Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 705 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.5 mg/kg Clear all
Completed Phase 2 Interventional Results available

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

NCT00525031
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 18, 2026, 1:03 PM EDT
Withdrawn Phase 4 Interventional

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

NCT02823977
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Ketamine, Dexmedetomidine, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01868893
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 18, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Early Phase 1 Interventional

Ketamine for MS Fatigue

NCT06064162
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ketamine
Drug
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

NCT01106833
View directory record Official record
Conditions
Chronic GVHD
Interventions
Sirolimus + calcineurin inhibitor + prednisone, Sirolimus + prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
31
States / cities
Duarte, California • La Jolla, California • Stanford, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

NCT04117711
View directory record Official record
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 18, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

NCT03196284
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
Concizumab, Eptacog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 18, 2026, 1:03 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01035216
View directory record Official record
Conditions
Leukemia
Interventions
GNKG168
Drug
Lead sponsor
SBI Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
La Jolla, California • Minneapolis, Minnesota • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225
View directory record Official record
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 18, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Chronic Kid's (KiCK) Pain

NCT01755169
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

NCT01010061
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Safety of Sildenafil in Premature Infants

NCT03142568
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

NCT00066482
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Interventions
bleomycin sulfate, filgrastim, cisplatin, cyclophosphamide, etoposide, conventional surgery, MESNA
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Sep 18, 2026, 1:03 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 18, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

NCT00610311
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
cyclophosphamide, fludarabine phosphate, Aldesleukin, ALVAC gp100 Vaccine, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Nasal Glucagon, Intramuscular Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264
View directory record Official record
Conditions
Primary Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 18, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation

NCT00997126
View directory record Official record
Conditions
Sedation
Interventions
Propofol, Alfentanil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 18, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

Comparing Safety and Efficacy of Dexmedetomidine and Propofol

NCT01152021
View directory record Official record
Conditions
Safety and Efficacy of Sedation Medications
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 18, 2026, 1:03 PM EDT